GLP-1 Weight-Loss Drugs and Pancreatitis: What the Evidence Says

What is acute pancreatitis?

Acute pancreatitis is sudden inflammation of the pancreas, the organ behind your stomach that makes digestive enzymes and insulin. It is a medical emergency. According to the NHS, the main symptom is tummy pain that can start suddenly and not go away, may be severe, sharp or knife-like, and can spread to your sides and back; it often feels worse after eating and may ease when you lean forward. It can also come with a high temperature, nausea and vomiting. The two most common causes overall are gallstones and heavy alcohol use.

Do GLP-1 medicines cause pancreatitis?

The honest, evidence-led answer is: a link is possible but has not been proven, and any risk appears to be small. Two things are true at the same time, and it helps to hold both:

• Randomised trials have been reassuring. When results from large randomised controlled trials are pooled together, they do not show a statistically significant increase in acute pancreatitis for GLP-1 medicines compared with placebo. For example, a pooled analysis of cardiovascular outcome trials in over 56,000 people with type 2 diabetes found no significant increase in acute pancreatitis, and a 2024 pooled analysis of semaglutide trials likewise found no significant excess.
• Real-world reports still occur. Regulators receive spontaneous reports of pancreatitis in people using these medicines. Because many of these people have diabetes, obesity or gallstone risk factors — which themselves raise pancreatitis risk — it is genuinely hard to know how much, if any, is caused by the drug itself.

This is why the safety information errs on the side of caution: pancreatitis is listed as an uncommon but serious possible side effect, and these medicines are not recommended for people who have had pancreatitis before.

What the UK regulator (MHRA) is doing

In the UK, medicine safety is overseen by the Medicines and Healthcare products Regulatory Agency (MHRA). In response to reports of acute pancreatitis in people taking GLP-1 medicines, the MHRA and Genomics England launched a Yellow Card Biobank study, announced on 26 June 2025. It asked people who had been hospitalised with acute pancreatitis while taking a GLP-1 medicine (brands named included Ozempic, Wegovy and Mounjaro) to come forward and provide a saliva sample, so researchers can explore whether a person's genetic makeup makes them more likely to develop pancreatitis on these drugs. The MHRA continues to encourage anyone who has experienced acute pancreatitis while taking a GLP-1 medicine to report it through the Yellow Card scheme.

The MHRA has also updated its guidance for GLP-1 prescribers and patients (29 January 2026), reminding patients to watch for the symptoms of pancreatitis — described as severe, persistent stomach pain that may spread to the back, with nausea and vomiting — to speak to a healthcare professional if this happens, and to report it via the Yellow Card scheme.

Who is most at risk?

• Anyone with a history of pancreatitis. GLP-1 medicines are not recommended if you have had pancreatitis before — tell your prescriber if this applies to you.
• People with gallstones or gallbladder disease, or those losing weight very rapidly (rapid weight loss raises the chance of new gallstones).
• Heavy alcohol use and very high blood triglyceride (fat) levels are independent causes of pancreatitis.

Your GP, pharmacist or specialist can weigh these factors up with you before you start, and check them again if anything changes.

Do you need blood tests while taking a GLP-1 medicine?

For people without symptoms, routine testing of pancreatic enzymes (amylase and lipase) is not generally recommended, because mild enzyme rises can happen without any pancreatitis and can cause needless worry. The important trigger is symptoms: if you develop new, severe abdominal pain, you should be assessed urgently and have your pancreatic enzymes checked before continuing the medicine. Follow your clinician's advice on any monitoring specific to you.

Related reading